Ernexa Therapeutics (ERNAW) Free Cash Flow (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Free Cash Flow data on file, last reported at -$2.3 million in Q1 2026.

• Quarterly Free Cash Flow fell 9.79% year-over-year to -$2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.3 million (up 48.36% YoY) and the FY2025 annual result came in at -$7.1 million, up 55.45% from the prior year.
• Free Cash Flow declined to -$2.3 million in Q1 2026, from -$1.2 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$1.2 million in Q4 2025 to a low of -$8.3 million in Q3 2023.
• A 5-year average of -$4.0 million and a median of -$3.8 million in 2024 frame the typical range for Free Cash Flow.
• The widest YoY moves for Free Cash Flow: up 78.96% in 2022, down 136.23% in 2022.
• Tracing ERNAW's Free Cash Flow over 5 years: stood at -$5.8 million in 2022, then soared by 69.53% to -$1.8 million in 2023, then sank by 100.34% to -$3.5 million in 2024, then soared by 66.51% to -$1.2 million in 2025, then tumbled by 90.9% to -$2.3 million in 2026.
• The last three Free Cash Flow figures came in at -$2.3 million (Q1 2026), -$1.2 million (Q4 2025), and -$1.3 million (Q3 2025), per Business Quant data.